Comparative phenotypic and genotypic analysis of community-acquired and hospital-acquired intra-abdominal infections among liver transplanted patients

J Appl Microbiol. 2024 Apr 1;135(4):lxae076. doi: 10.1093/jambio/lxae076.

Abstract

Aim: During liver transplantation, both hospital-acquired (HA) and community-acquired (CA) intra-abdominal infections (IAIs) are involved causing life-threatening diseases. Therefore, comparative studies of aerobic and facultative anaerobic HA-IAIs and CA-IAIs after liver transplantation surgery are necessary.

Methods and results: The species of detected isolates (310) from intra-abdominal fluid were identified and classified into hospital-acquired intra-abdominal infections (HA-IAIs) and community-acquired intra-abdominal infections (CA-IAIs). Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii were the most commonly detected species. The resistant phenotypes were commonly detected among the HA-IAIs; however, the virulent phenotypes were the predominant strains of CA-IAIs. Regrettably, the resistance profiles were shocking, indicating the inefficacy of monotherapy in treating these isolates. Therefore, we confirmed the use of empirical combination therapies of amikacin and meropenem for treating all IAIs (FICI ≤ 0.5). Unfortunately, the high diversity and low clonality of all identified HA and CA-IAIs were announced with D-value in the range of 0.992-1.

Conclusion: This diversity proves that there are infinite numbers of infection sources inside and outside healthcare centers.

Keywords: E. coli; P. aeruginosa; acinetobacter; amikacin; klebsiella; meropenem.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Community-Acquired Infections* / drug therapy
  • Cross Infection* / drug therapy
  • Escherichia coli / genetics
  • Hospitals
  • Humans
  • Intraabdominal Infections* / drug therapy
  • Liver
  • Liver Transplantation* / adverse effects
  • Microbial Sensitivity Tests
  • Phenotype

Substances

  • Anti-Bacterial Agents